Panelists:
Rachel Fong
Director, Sales and Alliances
Integral Molecular
Darshil Patel, PhD
Associate Director, Preclinical Research
Cabaletta Bio
Donald Siegel, PhD, MD
Prof. of Pathology & Laboratory Medicine Director, Division of Transfusion Medicine & Therapeutic Pathology Director, Center for Advanced Cellular Therapies
Perelman School of Medicine, University of Pennsylvania
- Time:
Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding; however, their predictive value for in vivo safety and toxicity is poor. Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk antibody-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.
In this GEN webinar, our panelists will discuss their experiences using the MPA to rapidly identify potential off-target interactions, resulting in successful IND filings for CAR-T cell therapies where conventional approaches did not suffice. We will also describe the newest additions to this 6,000-protein cell array and the status of its consideration by the FDA as a qualified Drug Development Tool.
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.
Produced with support from:
